A detailed history of Bank Of America Corp transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 400,567 shares of RVMD stock, worth $23.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
400,567
Previous 544,086 26.38%
Holding current value
$23.8 Million
Previous $17.5 Million 11.34%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$30.14 - $40.68 $4.33 Million - $5.84 Million
-143,519 Reduced 26.38%
400,567 $15.5 Million
Q1 2024

May 15, 2024

BUY
$26.56 - $33.55 $7.92 Million - $10 Million
298,079 Added 121.17%
544,086 $17.5 Million
Q4 2023

Feb 14, 2024

BUY
$18.35 - $34.12 $505,102 - $939,187
27,526 Added 12.6%
246,007 $7.06 Million
Q2 2023

Aug 14, 2023

SELL
$20.28 - $27.0 $14.7 Million - $19.5 Million
-723,252 Reduced 76.8%
218,481 $5.84 Million
Q1 2023

May 12, 2023

BUY
$20.76 - $30.09 $10.4 Million - $15.1 Million
500,318 Added 113.34%
941,733 $20.4 Million
Q4 2022

Feb 10, 2023

BUY
$17.68 - $25.53 $3.96 Million - $5.72 Million
224,037 Added 103.06%
441,415 $10.5 Million
Q3 2022

Nov 14, 2022

BUY
$17.46 - $26.0 $1.95 Million - $2.91 Million
111,920 Added 106.13%
217,378 $4.29 Million
Q2 2022

Aug 12, 2022

SELL
$14.54 - $27.17 $1.53 Million - $2.86 Million
-105,117 Reduced 49.92%
105,458 $2.06 Million
Q1 2022

May 16, 2022

BUY
$17.31 - $26.4 $3.08 Million - $4.7 Million
178,069 Added 547.8%
210,575 $5.37 Million
Q4 2021

Feb 08, 2022

BUY
$24.35 - $33.7 $295,828 - $409,421
12,149 Added 59.68%
32,506 $818,000
Q3 2021

Nov 15, 2021

SELL
$23.95 - $33.41 $193,420 - $269,819
-8,076 Reduced 28.4%
20,357 $560,000
Q2 2021

Sep 13, 2021

BUY
$29.0 - $47.44 $824,557 - $1.35 Million
28,433 New
28,433 $902,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $5.21B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.